Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Companyâs oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCRBP
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCorbus Pharmaceuticals Holdings Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 24, 2014
āļāļĩāļāļĩāđāļCohen (Yuval)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ28
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 24
āļāļĩāđāļāļĒāļđāđ500 River Ridge Drive
āđāļĄāļ·āļāļNORWOOD
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02062
āđāļāļĢāļĻāļąāļāļāđ16179630103
āđāļ§āđāļāđāļāļāđhttps://www.corbuspharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCRBP
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 24, 2014
āļāļĩāļāļĩāđāļCohen (Yuval)
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Dominic Smethurst
Chief Medical Officer
Mr. Sean F. Moran, CPA
Chief Financial Officer
Mr. Alan F. Holmer, J.D.
Independent Director
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Independent Director
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Ian Hodgson, Ph.D.
Chief Operating Officer
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Dr. Anne Altmeyer, Ph.D.
Independent Director
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Dominic Smethurst
Chief Medical Officer
Mr. Sean F. Moran, CPA
Chief Financial Officer
Mr. Alan F. Holmer, J.D.
Independent Director
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Independent Director
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board